
Annual report 2024
added 12-27-2025
Brainsway Ltd. Cash Flow 2011-2026 | BWAY
Annual Cash Flow Brainsway Ltd.
| 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Operating Cash Flow |
- | - | - | 884 K | -1.44 M | -7.24 M | -3.77 M | -3.47 M | - | - | - | - | - | - |
All numbers in USD currency
Quarterly Cash Flow Brainsway Ltd.
| 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|
All numbers in USD currency
Cash Flow Statement is one of the three key financial reports of the company Brainsway Ltd., reflecting the actual cash inflows and outflows over a certain period. Unlike the income statement, which shows revenues and expenses on an accrual basis, the cash flow statement focuses on real cash flows — how much cash actually came into the company and how much was spent.
Main Sections of the Cash Flow Statement- Operating Activities
This section reflects cash flows related to the company’s core operations: receipts from sales of goods and services, payments to suppliers, employee salaries, taxes, and other operating expenses. Positive cash flow from operating activities indicates the viability of the business and its ability to generate cash. - Investing Activities
Shows cash movements related to the purchase and sale of long-term assets such as real estate, equipment, and investments in other companies. Negative cash flow here often indicates investments in growth, which can be a positive sign. - Financing Activities
Reflects the inflow and outflow of cash related to raising and repaying capital: issuing shares, loans, dividend payments, and loan repayments. This section shows how the company finances its activities and distributes profits.
The cash flow statement is important for investors because it allows them to assess the company’s real liquidity, showing whether it has enough cash to cover current obligations and investments — this is critical for financial stability. Additionally, it helps analyze the quality of earnings, since profits reported in the income statement can be "paper" profits and may not reflect actual cash inflows; the cash flow statement reveals this difference. The presence of free cash is also crucial for evaluating the company’s ability to finance growth and pay dividends, which is important for investors. Attention should also be paid to prolonged negative cash flows from operating activities, as this may serve as a warning sign of potential problems with the core business.
Cash flow statements of other stocks in the Diagnostics research sector
| Issuer | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|
|
Akumin
AKU
|
- | -17.87 % | $ 25.9 M | ||
|
Centogene N.V.
CNTG
|
- | -6.23 % | $ 30.6 M | ||
|
Accelerate Diagnostics
AXDX
|
- | -61.36 % | $ 2.46 M | ||
|
Burning Rock Biotech Limited
BNR
|
$ 20.15 | -2.3 % | $ 217 M | ||
|
Co-Diagnostics
CODX
|
$ 0.17 | -6.7 % | $ 4.99 M | ||
|
Biocept
BIOC
|
- | -13.05 % | $ 7.29 M | ||
|
Chembio Diagnostics
CEMI
|
- | 0.22 % | $ 16.8 M | ||
|
BioNano Genomics
BNGO
|
$ 1.53 | 2.0 % | $ 1.94 M | ||
|
Danaher Corporation
DHR
|
$ 228.92 | -0.76 % | $ 167 B | ||
|
Castle Biosciences
CSTL
|
$ 38.9 | -1.04 % | $ 1.08 B | ||
|
DexCom
DXCM
|
$ 66.37 | -1.03 % | $ 25.6 B | ||
|
DermTech
DMTK
|
- | -11.32 % | $ 2.94 M | ||
|
DarioHealth Corp.
DRIO
|
$ 11.38 | 6.36 % | $ 323 M | ||
|
Enzo Biochem
ENZ
|
- | -8.98 % | $ 14.8 K | ||
|
Exact Sciences Corporation
EXAS
|
$ 101.56 | -0.33 % | $ 18.8 B | ||
|
Fulgent Genetics
FLGT
|
$ 26.27 | -0.83 % | $ 794 M | ||
|
Global Cord Blood Corporation
CO
|
- | - | $ 399 M | ||
|
Genetic Technologies Limited
GENE
|
- | - | $ 7.1 B | ||
|
Genetron Holdings Limited
GTH
|
- | 0.12 % | $ 80.1 M | ||
|
CareDx, Inc
CDNA
|
$ 18.84 | -1.21 % | $ 1.01 B | ||
|
Celcuity
CELC
|
$ 99.74 | -0.18 % | $ 3.93 B | ||
|
Anixa Biosciences
ANIX
|
$ 3.12 | - | $ 99.5 K | ||
|
IQVIA Holdings
IQV
|
$ 225.41 | -1.0 % | $ 40.9 B | ||
|
Heska Corporation
HSKA
|
- | - | $ 1.31 B | ||
|
HTG Molecular Diagnostics
HTGM
|
- | -20.0 % | $ 1.06 M | ||
|
Guardant Health
GH
|
$ 102.14 | 1.53 % | $ 12.5 B | ||
|
Aspira Women's Health
AWH
|
- | -6.19 % | $ 10.5 M | ||
|
ENDRA Life Sciences
NDRA
|
$ 4.53 | -4.83 % | $ 2.43 M | ||
|
Illumina
ILMN
|
$ 131.16 | -1.2 % | $ 20.9 B | ||
|
Charles River Laboratories International
CRL
|
$ 199.48 | -1.24 % | $ 10.2 B | ||
|
Myriad Genetics
MYGN
|
$ 6.15 | -0.32 % | $ 557 M | ||
|
NeoGenomics
NEO
|
$ 11.76 | -3.84 % | $ 1.49 B | ||
|
National Research Corporation
NRC
|
$ 18.77 | 0.64 % | $ 461 M | ||
|
Quest Diagnostics Incorporated
DGX
|
$ 173.53 | -1.12 % | $ 19.3 B | ||
|
Biodesix
BDSX
|
$ 6.8 | 1.19 % | $ 882 M | ||
|
Motus GI Holdings
MOTS
|
- | -34.28 % | $ 263 K | ||
|
Laboratory Corporation of America Holdings
LH
|
$ 250.88 | -0.87 % | $ 21 B | ||
|
ICON Public Limited Company
ICLR
|
$ 182.22 | -0.43 % | $ 15 B | ||
|
IDEXX Laboratories
IDXX
|
$ 676.53 | -0.85 % | $ 55.8 B | ||
|
Lantheus Holdings
LNTH
|
$ 66.55 | -0.91 % | $ 4.61 B | ||
|
Mettler-Toledo International
MTD
|
$ 1 394.19 | -1.42 % | $ 29.6 B | ||
|
Agilent Technologies
A
|
$ 136.07 | -1.13 % | $ 41.4 B | ||
|
Biomerica
BMRA
|
$ 2.52 | 2.86 % | $ 5.79 M | ||
|
Bioventus
BVS
|
$ 7.44 | -0.13 % | $ 466 M | ||
|
Koninklijke Philips N.V.
PHG
|
$ 27.08 | -1.13 % | $ 20 B | ||
|
Neogen Corporation
NEOG
|
$ 6.99 | -0.85 % | $ 1.52 B |